Abstract
Oncogenic KRAS drives initiation and maintenance of pancreatic ductal adenocarcinoma (PDAC). Here, we show that engineered exosomes with KrasG12D specific siRNA (iExoKrasG12D) reveal impressive biodistribution in pancreas with negligible toxicity in preclinical studies in mice and Rhesus macaques. Clinical testing of iExoKrasG12D in the iEXPLORE (iExoKrasG12D in Pancreatic Cancer) Phase I study employed a classical 3+3 dose escalation design (Phase Ia), followed by an accelerated titration design (Phase Ib) (NCT03608631). Patients with advanced metastatic disease were enrolled after failure of multiple lines of therapy. iExoKrasG12D therapy was well-tolerated with no reported dose-limiting toxicity with some cases of stable disease response, and maximum tolerated infusion was not reached even at the highest dose. Downregulation of KRASG12D DNA and suppression of phopho-Erk was documented with increased intratumoral in CD8+ T cell infiltration in patient samples upon treatment. The CD8+ T cell recruitment priming by iExoKrasG12D informed on potential efficacy of immune checkpoint therapy and lead to validation testing in preclinical PDAC models. Combination therapy of iExoKrasG12D and anti-CTLA-4 antibodies, but not anti-PD1, revealed robust anti-tumor efficacy via FAS mediated CD8+ T cell anti-tumor activity. This first-in-human, precision medicine clinical trial offers new insights into priming of immunotherapy by oncogenic Kras inhibitor and an opportunistic combination therapy for PDAC patients.
Competing Interest Statement
A.M. is a consultant for Tezcat Biosciences and is named on a patent that has been licensed to Thrive Earlier Detection (an Exact Sciences company). C.H. reports research funding to institution from Sanofi, Avenge, Iovance, KSQ, Theolytics, BTG, Novartis, 280Bio, Astrazeneca, EMD Serono, Takeda, Obsidian, Genentech, BMS, Summit Therapeutics, Artidis and Immunogenesis and personal fees from Regeneron and stock options from Briacell outside the submitted work.
Clinical Trial
NCT03608631
Funding Statement
The work was partially supported by the Cancer Prevention and Research Institute of Texas. The iExoKrasG12D preclinical studies and Phase I trial were supported by the MD Anderson Moon Shot Program and in part by the Translational Molecular Pathology-Immunoprofiling Lab (TMP-IL) Moon Shots Platform. A.M. is supported by the Khalifa bin Zayed Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of MD Anderson Cancer Center gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
